Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis

Rockwell Medical Technologies, Inc.718 enrolled

Overview

The purpose of the parent study is to assess the short-term safety and tolerability of soluble ferric pyrophosphate (SFP) in dialysate administered to a large number of representative adult chronic kidney disease patients on hemodialysis (CKD-HD). The purpose of the extension study is to assess the long-term safety and tolerability of SFP.

Parent Study: randomized, double-blinded, crossover, up to 6 weeks, 700 patients. Patients were randomized to receive SFP 2 µmoles (110 µg) iron/L of dialysate in liquid bicarbonate concentrate or placebo (standard liquid bicarbonate concentrate) x 2 weeks, then a 1 week washout, then crossed over to the alternate treatment x 2 weeks. Extension Study: open-label, single active arm, uncontrolled study, up to 53 weeks, 300 patients. Following completion of the RMTI-SFP-6 parent study, patients could enter the extension study, where they received SFP 2 µmoles (110 µg) iron/L of dialysate in liquid bicarbonate concentrate for up to 52 weeks.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

718

Conditions

End Stage Renal Disease Chronic Kidney Disease

Interventions

SFPDRUG

Dialysis with SFP administered via the liquid bicarbonate concentrate at a concentration of 2 µmoles (110 µg) iron/L of dialysate

PlaceboOTHER

Dialysis with standard liquid bicarbonate concentrate without iron

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Parent Study, Double Blinded, Crossover: Key Inclusion Criteria: 1. Adult ≥ 18 years of age. 2. Has chronic kidney disease (CKD) receiving maintenance hemodialysis (HD) (CKD-HD subjects) and regularly undergoing 2 or more dialysis sessions per week. 3. Stable pre-dialysis Hgb ≥ 9.0 to ≤ 12.5 g/dL. 4. Stable pre-dialysis TSAT ≥ 15% to ≤ 45%. 5. Stable pre-dialysis ferritin ≥ 100 to ≤ 1200 µg/L (1200 ng/mL). Key Exclusion Criteria: 1. Any previous exposure to SFP. 2. Therapy with intravenous, intramuscular or oral iron at any time between the first/screening visit and the randomization visit, or anticipated requirement for iron supplementation during the study period. 3. Non-tunneled vascular catheter for dialysis. 4. Scheduled for kidney transplant within the next 8 weeks. 5. Active infection requiring systemic antimicrobial or antifungal therapy within 2 weeks prior to screening, or during screening period prior to randomization. 6. Hospitalization within 1 month prior to screening (except for vascular access surgery). Extension Study, Open Label, Single Active Arm: Key Inclusion Criteria: 1. Participated in Parent Study RMTI-SFP-6 and completed the follow-up/early term visit. 2. Hemoglobin ≤12.0 g/dL at screening. 3. TSAT ≤45% at screening. (Excursion of TSAT by ≤10% outside this range permitted only if all other inclusion/exclusion criteria are met). 4. Serum ferritin ≤1000 µg/L at screening. (Excursion of ferritin by ≤10% outside this range permitted only if all other inclusion/exclusion criteria are met). Key Exclusion Criteria: 1. Had a serious adverse event attributable (i.e., probably, possibly, or definitely related) to study drug or had an adverse event attributable to study drug that necessitated premature withdrawal from the double-blind, placebo-controlled crossover phase of the parent study RMTI-SFP-6. 2. Non-tunneled vascular catheter for dialysis. 3. Scheduled for kidney transplant within 12 weeks after entry into extension phase. 4. Active infection requiring systemic antimicrobial or antifungal therapy within 2 weeks prior to dosing. 5. Pregnancy or intention to become pregnant during the study.

Locations (31)

Unnamed facility

Mobile, Alabama, United States

Outcomes

Primary Outcomes

Incidence of Treatment-emergent Adverse Events

Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention.

Time frame: Up to 7 weeks for the Parent (Crossover) Study and up to 53 weeks for Extension Study

Incidence of Treatment-emergent Adverse Events of Intradialytic Hypotension

Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. For each adverse event, investigators assessed whether the event met the protocol criteria for intradialytic hypotension. Intradialytic hypotension events were only to have been reported as adverse events if they exceeded the individual subject's baseline pattern of intradialytic hypotension.

Time frame: Up to 7 weeks for the Parent (Crossover) Study and up to 53 weeks for Extension Study

Incidence of Related Suspected Hypersensitivity Reactions

Time frame: Up to 7 weeks for the Parent (Crossover) Study and up to 53 weeks for Extension Study

Secondary Outcomes

Incidence of Composite Cardiovascular Events

Adverse events for a given intervention (SFP or Placebo) are counted from the date of the first day of dosing of the intervention until 7 days after the last day of dosing of the intervention. Adverse event terms meeting criteria for composite cardiovascular events were pre-specified in the statistical analysis plan for the study.

Time frame: Up to 7 weeks for the Parent (Crossover) Study and up to 53 weeks for Extension Study

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.